CA3010097C - Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease - Google Patents

Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease Download PDF

Info

Publication number
CA3010097C
CA3010097C CA3010097A CA3010097A CA3010097C CA 3010097 C CA3010097 C CA 3010097C CA 3010097 A CA3010097 A CA 3010097A CA 3010097 A CA3010097 A CA 3010097A CA 3010097 C CA3010097 C CA 3010097C
Authority
CA
Canada
Prior art keywords
fatty liver
alcoholic fatty
liver disease
liver
hydroxyphenyladenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3010097A
Other languages
English (en)
French (fr)
Other versions
CA3010097A1 (en
Inventor
Haibo Zhu
Huijie SHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Gushen Life Health Technology Co Ltd, Institute of Materia Medica of CAMS and PUMC filed Critical Beijing Gushen Life Health Technology Co Ltd
Publication of CA3010097A1 publication Critical patent/CA3010097A1/en
Application granted granted Critical
Publication of CA3010097C publication Critical patent/CA3010097C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3010097A 2015-12-31 2016-12-28 Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease Active CA3010097C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511034199.0 2015-12-31
CN201511034199 2015-12-31
PCT/CN2016/112623 WO2017114413A1 (zh) 2015-12-31 2016-12-28 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (2)

Publication Number Publication Date
CA3010097A1 CA3010097A1 (en) 2017-07-06
CA3010097C true CA3010097C (en) 2023-08-22

Family

ID=59224622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010097A Active CA3010097C (en) 2015-12-31 2016-12-28 Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease

Country Status (11)

Country Link
US (1) US11058703B2 (https=)
EP (1) EP3398604A4 (https=)
JP (1) JP7382716B2 (https=)
KR (1) KR102676056B1 (https=)
CN (2) CN118178446A (https=)
AU (1) AU2016383376B2 (https=)
CA (1) CA3010097C (https=)
HK (1) HK1255689A1 (https=)
RU (1) RU2759916C2 (https=)
WO (1) WO2017114413A1 (https=)
ZA (1) ZA201805080B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用
CN117599076A (zh) * 2023-11-15 2024-02-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
AU2012245996B2 (en) * 2011-04-22 2016-09-01 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) * 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Also Published As

Publication number Publication date
KR20180100152A (ko) 2018-09-07
CN106943420A (zh) 2017-07-14
KR102676056B1 (ko) 2024-06-19
HK1255689A1 (en) 2019-08-23
JP7382716B2 (ja) 2023-11-17
CA3010097A1 (en) 2017-07-06
AU2016383376B2 (en) 2022-07-28
US11058703B2 (en) 2021-07-13
EP3398604A1 (en) 2018-11-07
RU2018126158A (ru) 2020-01-31
WO2017114413A1 (zh) 2017-07-06
ZA201805080B (en) 2019-10-30
CN118178446A (zh) 2024-06-14
RU2759916C2 (ru) 2021-11-18
US20190022120A1 (en) 2019-01-24
JP2019500379A (ja) 2019-01-10
RU2018126158A3 (https=) 2020-03-11
EP3398604A4 (en) 2019-06-19
AU2016383376A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
CA3010097C (en) Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
US11903932B2 (en) Use of dihydroberberine or its derivatives to enhance muscle function
CN101181373B (zh) 丹皮有效部位药物组合物、其制备方法及应用
CN117599036A (zh) 隐绿原酸在制备治疗和/或预防非酒精性脂肪肝产品中的用途
JPWO2019106851A1 (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）および／または非アルコール性脂肪性肝炎（ｎａｓｈ）、および／または肝脂肪性変性の治療と予防に適した、配合剤
CN106176773A (zh) 盐酸小檗碱和水苏糖组成的组合物及其应用
US20130303611A1 (en) Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis
CN116270676A (zh) 甘露特钠在制备预防或治疗肥胖及相关代谢性疾病药物中的应用
US20190070208A1 (en) Use of triacetyl-3-hydroxyphenyladenosine in preparing pharmaceuticals for treatment of atherosclerosis
WO2025103336A1 (zh) 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用
CN106727480B (zh) Fex-3在制备抗肥胖症药物中的应用
CN114788825A (zh) Magl抑制剂的医药用途
CN109985072A (zh) 榆黄蘑提取物在制备治疗脂肪肝的药物、保健品、食品中的应用
CN111686239B (zh) 抗真菌化合物的应用
CN103735549A (zh) 盐酸去亚甲基小檗碱在制备治疗非酒精性脂肪肝病药物中的应用
CN113181178A (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗疼痛药物中的应用
TW202239401A (zh) 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
KR20070044198A (ko) 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제
CN117100739B (zh) 负调节Nrf2信号通路的小分子组合物及其应用
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
TWI466676B (zh) 一種大和當歸萃取物之用途
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用
KR20260033973A (ko) 오에노테인 b를 포함하는 대사이상 간 질환의 예방 또는 치료용 조성물
CA3017400C (en) Use of triacetyl-3-hydroxyphenyladenosine for treatment of hyperlipidemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210924

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126